{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:38:51Z","timestamp":1788485931356,"version":"build-2803163510"},"reference-count":37,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"argenx BV","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,29]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a rare, chronic, autoimmune disease, mediated by immunoglobulin G antibodies, which causes debilitating muscle weakness. As with most rare diseases, there is little patient-reported data with which to understand and address patient needs. This study explores the impact of MG in the real world from the patient perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a 2-year prospective, observational, digital, longitudinal study of adults with MG, resident in the following countries: the USA, Japan, Germany, France, the UK, Italy, Spain, Canada and Belgium. The planned sample size is 2000. Recruitment will be community based, via patient advocacy groups, social media and word of mouth. Participants will use a smartphone application (app) to check eligibility, provide consent and contribute data. Planned data entry is as follows: (1) personal profile on enrollment\u2014covering demographics, MG characteristics and previous care; (2) monthly event tracker\u2014current treatments, healthcare visits, treatment-related adverse events, productivity losses; (3) monthly selection of validated generic and disease-specific patient-reported outcomes instruments: EQ-5D-5L, Myasthenia Gravis Activities of Daily Living, Myasthenia Gravis Quality of Life 15-item revised scale, Hospital Anxiety and Depression Scale and Health Utilities Index III. Analyses are planned for when the study has been running in most countries for approximately 6, 12, 18 and 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been reviewed and granted ethics approval by Salus IRB for participants resident in the following countries: Germany, the UK and the US. Local ethics approval is being sought for the following study countries: Belgium, Canada, France, Italy, Japan and Spain. Study results will be communicated to the public and participants via conference presentations and journal publications, as well as regular email, social media and in-application communication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04176211\">NCT04176211<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-048198","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T12:10:23Z","timestamp":1626783023000},"page":"e048198","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04176211","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sonia","family":"Berrih-Aknin","sequence":"first","affiliation":[{"name":"INSERM, Institute of Myology, Center of Research in Myology, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G","family":"Claeys","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Law","sequence":"additional","affiliation":[{"name":"Myasthenia Gravis Foundation of America Inc, Westborough, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy"},{"name":"Associazione Italiana Miastenia e Malattie Immunodegenerative, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Neurology, International University of Health and Welfare, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[{"name":"DNSRO Department, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dewilde","sequence":"additional","affiliation":[{"name":"Services in Health Economics, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu F","family":"Janssen","sequence":"additional","affiliation":[{"name":"Section Medical Psychology and Psychotherapy, Department of Psychiatry, Erasmus MC, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-1303","authenticated-orcid":false,"given":"Emma","family":"Bagshaw","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hara","family":"Kousoulakou","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Larkin","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Leighton","sequence":"additional","affiliation":[{"name":"argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Paci","sequence":"additional","affiliation":[{"name":"argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"2025121511190653000_11.7.e048198.1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025121511190653000_11.7.e048198.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.011"},{"key":"2025121511190653000_11.7.e048198.3","unstructured":"National Institute of Neurological Disorders and Stroke . Myasthenia gravis fact sheet, 2018. Available: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Myasthenia-Gravis-Fact-Sheet"},{"key":"2025121511190653000_11.7.e048198.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894"},{"key":"2025121511190653000_11.7.e048198.5","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.12703","article-title":"Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry","volume":"22","author":"Ramos-Fransi","year":"2015","journal-title":"Eur J Neurol"},{"key":"2025121511190653000_11.7.e048198.6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829595"},{"key":"2025121511190653000_11.7.e048198.7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0972-2327.112466","article-title":"Clinical profile and outcome of myasthenic crisis in a tertiary care Hospital: a prospective study","volume":"16","author":"Sharma","year":"2013","journal-title":"Ann Indian Acad Neurol"},{"key":"2025121511190653000_11.7.e048198.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5.1253"},{"key":"2025121511190653000_11.7.e048198.9","unstructured":"The Centre for International Economics . The cost to patients and the community of myasthenia gravis: understanding the patient experience and community wide impact, 2014. Available: http:\/\/www.thecie.com.au\/wp-content\/uploads\/2014\/06\/Final-report_Economic-Impact-of-Myasthenia-Gravis-08112013.pdf [Accessed Nov 2020]."},{"key":"2025121511190653000_11.7.e048198.10","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2025121511190653000_11.7.e048198.11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","article-title":"Quality of life in 188 patients with myasthenia gravis in China","volume":"126","author":"Yang","year":"2016","journal-title":"Int J Neurosci"},{"key":"2025121511190653000_11.7.e048198.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025121511190653000_11.7.e048198.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b907b"},{"key":"2025121511190653000_11.7.e048198.14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002790"},{"key":"2025121511190653000_11.7.e048198.15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025121511190653000_11.7.e048198.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"2025121511190653000_11.7.e048198.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1123-4","article-title":"Share and protect our health data: an evidence based approach to rare disease patients\" perspectives on data sharing and data protection - quantitative survey and recommendations","volume":"14","author":"Courbier","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025121511190653000_11.7.e048198.18","unstructured":"Commission of the European Communities . Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe\u2019s Challenges {SEC(2008)2713} {SEC(2008)2712}, 2008. Available: http:\/\/www.europlanproject.eu\/Resources\/docs\/ECCommunication_COM-2008-679final.pdf [Accessed Nov 2020]."},{"key":"2025121511190653000_11.7.e048198.19","unstructured":"Eurordis: rare diseases Europe. Eurordis policy fact sheet: needs and priorities for rare disease research.. Available: http:\/\/download2.eurordis.org\/europlan\/3_EURORDIS_Guidance_Documents_for_the_National_Conference\/Factsheet_Research.pdf [Accessed Nov 2020]."},{"key":"2025121511190653000_11.7.e048198.20","unstructured":"EUROPLAN: European project for rare disease national plan development. EUROPLAN project. Available: http:\/\/www.europlanproject.eu\/Content?folder=1 [Accessed Nov 2020]."},{"key":"2025121511190653000_11.7.e048198.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121511190653000_11.7.e048198.22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jval.2018.07.001","article-title":"Selecting Bolt-On dimensions for the EQ-5D: examining their contribution to health-related quality of life","volume":"22","author":"Finch","year":"2019","journal-title":"Value Health"},{"key":"2025121511190653000_11.7.e048198.23","doi-asserted-by":"publisher","DOI":"10.3310\/hta18520"},{"key":"2025121511190653000_11.7.e048198.24","doi-asserted-by":"crossref","first-page":"361-368","DOI":"10.3961\/jpmph.16.076","article-title":"Exploratory study of dimensions of health-related quality of life in the general population of South Korea","volume":"50","author":"Kim","year":"2017","journal-title":"J Prev Med Public Health"},{"key":"2025121511190653000_11.7.e048198.25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/0272989X19847983","article-title":"Exploring the impact of adding a respiratory dimension to the EQ-5D-5L","volume":"39","author":"Hoogendoorn","year":"2019","journal-title":"Med Decis Making"},{"key":"2025121511190653000_11.7.e048198.26","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13480428"},{"key":"2025121511190653000_11.7.e048198.27","doi-asserted-by":"crossref","first-page":"1156-62","DOI":"10.1016\/j.jval.2013.10.003","article-title":"Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK","volume":"16","author":"Swinburn","year":"2013","journal-title":"Value Health"},{"key":"2025121511190653000_11.7.e048198.28","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"2025121511190653000_11.7.e048198.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"2025121511190653000_11.7.e048198.30","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"2025121511190653000_11.7.e048198.31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International Clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"2025121511190653000_11.7.e048198.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025121511190653000_11.7.e048198.33","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqu024"},{"key":"2025121511190653000_11.7.e048198.34","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-54"},{"key":"2025121511190653000_11.7.e048198.35","unstructured":"Patient-Reported Outcomes Measurement Information System . Dyspnea. A brief guide to the PROMIS\u00a9 dyspnea instruments, 2017. Available: http:\/\/www.healthmeasures.net\/images\/PROMIS\/manuals\/PROMIS_Dyspnea_Scoring_Manual.pdf"},{"key":"2025121511190653000_11.7.e048198.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"2025121511190653000_11.7.e048198.37","first-page":"353","article-title":"Measurement properties of PROMIS sleep disturbance short forms in a large, ethnically diverse cancer cohort","volume":"58","author":"Jensen","year":"2016","journal-title":"Psychol Test Assess Model"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-048198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:19:13Z","timestamp":1765826353000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-048198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,20]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bmjopen-2020-048198"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-048198","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}